Effects of Macrolide Treatment during the Hospitalization of Children with Childhood Wheezing Disease: A Systematic Review and Meta-Analysis

J. Clin. Med. 20187(11), 432; https://doi.org/10.3390/jcm7110432
 
Abstract
Children are susceptible to a variety of respiratory infections. Wheezing is a common sign presented by children with respiratory infections. Asthma, bronchiolitis, and bronchitis are common causes of childhood wheezing disease (CWD) and are regarded as overlapping disease spectra. Macrolides are common antimicrobial agents with anti-inflammatory effects. We conducted a comprehensive literature search and a systematic review of studies that investigated the influences of macrolide treatment on CWD. The primary outcomes were the impact of macrolides on hospitalization courses of patients with CWD. Data pertaining to the study population, macrolide treatment, hospital courses, and recurrences were analyzed. Twenty-three studies with a combined study population of 2210 patients were included in the systematic review. Any kind of benefit from macrolide treatment was observed in approximately two-thirds of the studies (15/23). Eight studies were included in the meta-analysis to investigate the influence of macrolides on the length of stay (LOS), duration of oxygen demand (DOD), symptoms and signs of respiratory distress, and re-admission rates. Although the benefits of macrolide treatment were reported in several of the studies, no significant differences in LOS, DOD, symptoms and signs of respiratory distress, or re-admission rates were observed in patients undergoing macrolide treatment. In conclusion, any kind of benefit of macrolide treatment was observed in approximately two-thirds of the studies; however, no obvious benefits of macrolide treatment were observed in the hospitalization courses of children with CWD. The routine use of macrolides to improve the hospitalization course of children with CWD is not suggested. 
Full-Text   |    PDF 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: WORLD ALLERGY CONGRESS | WAC2019 - WORLD ALLERGY CONGRESS https://t.co/KpUHk6kq9r, see more https://t.co/CpGiFuOOYd
4hreplyretweetfavorite
Interasma RT @worldallergy: Top story: Conjunctivitis Seen in Patients on Dupixent | Medpage Today https://t.co/WzoMs3nmNr, see more https://t.co/yY2
10hreplyretweetfavorite
Interasma RT @WAOJM: Beirut, Lebanon - 4-6 April 2019 Visit the WISC 2019 Website for details! https://t.co/Hz6qBiFuIm
10hreplyretweetfavorite
Interasma RT @AllergyEaaci: How to discontinue omalizumab in chronic spontaneous urticaria? Download Article Here: https://t.co/CnLrzLyZ4J #allergy #…
10hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma